Viewing Study NCT00002154



Ignite Creation Date: 2024-05-05 @ 10:00 AM
Last Modification Date: 2024-10-26 @ 9:02 AM
Study NCT ID: NCT00002154
Status: COMPLETED
Last Update Posted: 2005-06-24
First Post: 1999-11-02

Brief Title: A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia
Sponsor: The Dana Foundation
Organization: NIH AIDS Clinical Trials Information Service

Study Overview

Official Title: Parallel Group Placebo-Controlled Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia
Status: COMPLETED
Status Verified Date: 1996-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl selegiline hydrochloride alone or in combination to HIV-infected patients who have mild to moderate dementia a decline in their mental abilities
Detailed Description: Patients are randomized to receive thioctic acid alone deprenyl alone thioctic aciddeprenyl or placebo alone for 10 weeks after which all patients may receive active drug on an open-label basis Patients must have seven clinic visits

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
03-D95 None None None